AN 215

Drug Profile

AN 215

Alternative Names: AN-215

Latest Information Update: 06 Oct 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AEterna Zentaris Inc; Tulane University School of Medicine; Zentaris
  • Developer AEterna Zentaris GmbH; Tulane University School of Medicine
  • Class Antineoplastics
  • Mechanism of Action DNA intercalators; Gastrin-releasing peptide inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 06 Oct 2008 Discontinued - Preclinical for Solid tumours in USA (IV)
  • 01 Jun 2006 This compound is still in active development
  • 27 Oct 2005 A preclinical study has been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top